Karaca, F.Keskin, S.Mentes, S.Boga, Z.Cavus, G.Koksal, F.2025-05-102025-05-1020231119-30772229-773110.4103/njcp.njcp_800_222-s2.0-85176370853https://doi.org/10.4103/njcp.njcp_800_22https://hdl.handle.net/20.500.14720/9665Background: This study evaluated the change in IL-16 levels in patients with high-grade glial tumors undergoing radiotherapy (RT) and healthy individuals (control group).Materials and Methods: Serum IL-16 levels of 35 high-grade glioma patients receiving radiotherapy (RT) and 30 healthy individuals were compared. We compared the IL-16 levels before (RT0) and after the (RT1) and IL-16 levels were measured and the relationship of this change with other characteristics such as age, gender, weight, height, and blood test results. Results: The RT0-IL-16 level was approximately 15 pg/ml higher than the RT1 measurement in the patient group. The mean RT0-IL-16 levels in the patient group were approximately 10 pg/ml higher than the mean IL-16 levels in the control group. Likewise, at the RT1 time-point, the mean IL-16 levels for the patient group were approximately 5 pg/ml lower than the mean IL-16 for the control group. The mean RT0-RT1-IL-16 value tended to be higher in female patients than in male patients. Conclusion: The application of RT reduces the overall IL-16 levels, suggesting the efficacy of RT, as well as the role of IL-16 in tumorigenesis.eninfo:eu-repo/semantics/openAccessIl-16Malignant GliomaRadiotherapyArticle2610Q4Q21456146237929521WOS:001094966700008